Proton Pump Inhibitors Market Trends, Key Players, Analysis, Trends And Forecast 2024-2033

The proton pump inhibitors market size has grown steadily in recent years. It will grow from $3.3 billion in 2023 to $3.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to prevalence of gastroesophageal reflux disease (gerd), peptic ulcer disease incidence, rising aging population, changing lifestyles and dietary habits, increasing awareness and diagnosis.

The proton pump inhibitors market size is expected to see steady growth in the next few years. It will grow to $4.12 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emerging markets adoption, growth in helicobacter pylori infections, patient education initiatives, strategic marketing and promotions. Major trends in the forecast period include integration with digital health solutions, global market expansion, focus on gastrointestinal health education, regulatory updates and safety measures, environmental impact considerations.

Market Overview -
Proton pump inhibitors (PPIs) are a class of medications that reduce the production of acid by the stomach. Proton pump inhibitors (PPIs) are used to treat conditions that are caused by either an overproduction of stomach acid or exacerbated by stomach acid, such as acid reflux, and stomach ulcers.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10791&type=smp

Rising Incidence Of Gastrointestinal Disorders Fuels Surge In Proton Pump Inhibitors Market
The increasing prevalence of gastrointestinal disorders is expected to drive the growth of the proton pump inhibitors market. Gastrointestinal disorders refer to a collective term of diseases such as nausea, vomiting, food poisoning, and diarrhea that impact the overall biological functioning of the gastrointestinal (GI) tract. Proton pump inhibitors (PPIs) are commonly prescribed as a medication for treating heartburn and acid-related disorders. PPIs reduce the amount of stomach acid made by glands in the stomach lining. The increasing prevalence of gastrointestinal disorders contributes to proton pump inhibitors' growth. For instance, in September 2022, according to Cancer Australia, an Australia-based cancer control group to support cancer patients and raise awareness of the illness, Australia is predicted to see 2,572 new cases of stomach cancer in 2022 (1,661 male cases and 911 female cases). Similarly, in September 2022, according to a survey by the American Gastroenterological Association, a US-based medical association for gastroenterologists with more than 16,000 doctors and scientists as members, due to severe gastrointestinal symptoms, over 40% of Americans have stopped engaging in daily activities in the last year, such as working exercise (19%), finishing tasks (17%), and socializing with friends and family (16%). Therefore, the increasing prevalence of gastrointestinal disorders is expected to propel the growth of the proton pump inhibitors market.

Competitive Landscape -
Major companies operating in the proton pump inhibitors market report are AstraZeneca plc, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company, Santarus Inc., Janssen Pharmaceuticals, GlaxoSmithKline plc, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Sanofi S.A., Johnson & Johnson, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Cipla Limited, Hetero Drugs Limited, Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Limited, Panacea Biotec Ltd., Strides Pharma Science Limited, Wockhardt Ltd.

Xiromed's Innovative Entry Launch Of Omeprazole Delayed-Release Capsules Signals Advancements In Proton Pump Inhibitors Market
Product innovation is a key trend gaining popularity in the proton pump inhibitors market. Major companies operating in the proton pump inhibitors market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in March 2021, Xiromed LLC, a US-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20mg, a generic version of Prilosec, used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions caused by excess stomach acid. Omeprazole is a proton pump inhibitor used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the over secretion of gastric acid.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Key Segments -
The proton pump inhibitors market covered in this report is segmented -
1) By Type: Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Dexlansoprazole, Other Types
2) By Disease Allocation: Ulcers, Gastroesophageal Reflux Disease, Other Disease Indications
3) By Application: Hospitals, Clinic, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.